RESEARCH MONOGRAPH · KDC-MN-1325

Adamax

May 9, 2026 Kodiac biolabs Research Revised May 19, 2026 2 min read

Our opinion on this compound

34/100

Adamantyl-Semax hybrid with almost no Western data. Speculative even by Khavinson-adjacent standards

Honestly the literature on adamax (adamantyl-conjugated ACTH 4-7 Pro-Gly-Pro, basically an adamantane-modified Semax derivative) is so thin that we're going to hedge hard here. There are a small number of Russian papers proposing it as an extended-half-life Semax variant with improved blood-brain barrier penetration, and that's about it.

The design rationale makes pharmacological sense in principle. Adamantyl conjugation to peptide N-termini does increase lipid solubility, can extend metabolic half-life by sterically blocking N-terminal aminopeptidase cleavage, and the adamantane group itself has some intrinsic CNS pharmacology (amantadine pedigree). So you could imagine the resulting compound combining Semax-like neurotrophic effects with longer duration and possibly some NMDA antagonist activity from the adamantyl portion. That's the design story.

The problem is the empirical evidence. We dont know of any Western replication of the proposed pharmacological effects, no clean pharmacokinetic characterization in humans, and the Russian publications are mostly behavioral rodent work from a small number of groups. The mechanism claims (BDNF and NGF upregulation, like the parent Semax) are stated more than demonstrated in clean dose-response form.

What we'd actually want is independent characterization of the binding profile (does the adamantyl group preserve the melanocortin-receptor-adjacent activity of the parent peptide? does it add NMDA activity?), proper pharmacokinetic work, and replicated behavioral effects from non-affiliated labs. None of that exists in any form we can find.

For research use this is firmly in the speculative-tool-compound category. If you're already running Semax variants and want to test the lipid-solubility hypothesis with a conjugated derivative, adamax is one option, but you should treat any results with appropriate caution.

Sourcing is poor. Material that's marketed as adamax varies substantially in synthesis quality and the structural confirmation often relies entirely on the supplier's HPLC data without independent verification. We'd verify by mass spec and at least 1D NMR before doing anything with it.

Staying power is low. Without independent replication this stays a fringe Russian-origin compound.

Evidence: 20
Mechanism: 35
Reliability: 30
Safety: 55
Sourcing: 40
Value: 40
Signal: 30
Staying power: 25

Adamantyl-conjugated ACTH(4-7)-Pro-Gly-Pro nootropic peptide

A blood-brain-barrier-penetrant adamantyl conjugate of the Semax heptapeptide developed at the Russian Academy of Sciences for sustained nootropic exposure.

Abstract

Adamax (adamantyl-Met-Glu-His-Phe-Pro-Gly-Pro; molecular weight approximately 980 Da) is a synthetic nootropic peptide developed at the Russian Academy of Sciences as a blood-brain-barrier-penetrant variant of Semax (the ACTH(4-10) analog Met-Glu-His-Phe-Pro-Gly-Pro). The structural modification is N-terminal conjugation of an adamantyl group to the methionine residue, increasing lipophilicity by approximately three log units and extending the half-life in cerebrospinal fluid relative to the parent heptapeptide, which has an intranasal central exposure of only minutes. The pharmacological signature mirrors Semax: BDNF and NGF transcriptional upregulation in cortex and hippocampus, pro-cognitive effects in passive avoidance and Morris water maze rodent models, and neuroprotective activity in middle cerebral artery occlusion stroke models. The adamantyl modification additionally enables oral and parenteral administration with central exposure, in contrast to the intranasal-restricted parent. The compound is a research-grade peptide with limited Western pharmacology characterization; the principal published record is in Russian-language journals from the Institute of Molecular Genetics RAS. Adamax is not approved by any regulatory authority and is not in active clinical development. Investigators should treat the compound as a research tool for studying central exposure of ACTH-derived heptapeptides under conditions where the parent Semax cannot be delivered intranasally. Reconstitution and handling parallel other small peptides; the adamantyl modification reduces aqueous solubility and may require co-solvent or DMSO stock for in vitro work.

Mechanism of action

BDNF and NGF transcriptional upregulation. Adamantyl conjugation increases lipophilicity and BBB penetration relative to parent Semax, extending CSF exposure.

Reported research dose ranges

Rodent studies report 0.1 to 1 mg/kg subcutaneously or per os. No human clinical data.

References

Levitskaya NG, et al. Effects of adamantane-conjugated heptapeptide on learning and memory. Bull Exp Biol Med 2012.
Myasoedov NF, et al. Regulatory peptides in clinical practice. Vestnik RAMS 2014.
Andreeva LA, et al. Synthesis of lipophilic Semax analogues. Russ J Bioorg Chem 2010.

Read the full monograph

The full reference document is available below as a PDF embed and download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-1325 Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Adamax

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs